Evidence map›Paper›PMID 38239353›Full record

ReviewFrontiers in immunology2023

Role of MCP-1 as an inflammatory biomarker in nephropathy.

Yanlong Liu, Ke Xu, Yuhua Xiang, Boyan Ma, Hailong Li, Yuan Li, Yue Shi, Shuju Li, Yan Bai

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
25.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Hydrating with a higher-fructose sport drink does not worsen acute kidney injury risk during simulated work-related heat stress.American journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Synergistic venetoclax and anti-CD3 therapy for control of alloreactive response in hematopoietic stem cell transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yanlong LiuHeilongjiang Provincial Health Commission, Harbin, China.
Ke XuHeilongjiang University of Chinese Medicine, The Second Clinical Medical College, Harbin, China.
Yuhua XiangHeilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
Boyan MaHeilongjiang University of Chinese Medicine, The Second Clinical Medical College, Harbin, China.
Hailong LiHeilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
Yuan LiThe First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yue ShiHeilongjiang University of Chinese Medicine, The Second Clinical Medical College, Harbin, China.
Shuju LiHeilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
Yan BaiHeilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
Heilongjiang Academy of Forestry · CNHeilongjiang University of Chinese Medicine · CNHarbin Medical University · CNHealth Commission of Anhui Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Monocyte chemoattractant protein-1 (MCP-1), also referred to as chemokine ligand 2 (CCL2), belongs to the extensive chemokine family and serves as a crucial mediator of innate immunity and tissue inflammation. It has a notable impact on inflammatory conditions affecting the kidneys. Upon binding to its receptor, MCP-1 can induce lymphocytes and NK cells' homing, migration, activation, differentiation, and development while promoting monocytes' and macrophages' infiltration, thereby facilitating kidney disease-related inflammation. As a biomarker for kidney disease, MCP-1 has made notable advancements in primary kidney diseases such as crescentic glomerulonephritis, chronic glomerulonephritis, primary glomerulopathy, idiopathic proteinuria glomerulopathy, acute kidney injury; secondary kidney diseases like diabetic nephropathy and lupus nephritis; hereditary kidney diseases including autosomal dominant polycystic kidney disease and sickle cell kidney disease. MCP-1 not only predicts the occurrence, progression, prognosis of the disease but is also closely associated with the severity and stage of nephropathy. When renal tissue is stimulated or experiences significant damage, the expression of MCP-1 increases, demonstrating a direct correlation with the severity of renal injury.

Indexed as

Diabetic NephropathiesGlomerulonephritisLupus NephritisBiomarkersChemokine CCL2HumansInflammationBiomarkersChemokine CCL2hereditary nephropathyinflammatory markersMCP-1primary nephropathysecondary nephropathy

Identifiers

PMID38239353
PMCPMC10794684
OpenAlexW4390584046

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.